Cereno Scientific publishes an additional document in conjunction with admission to trading on Nasdaq First North Growth Market

Cereno Scientific AB ("Cereno Scientific" or the "Company") publishes an additional document (the “Document”) in conjunction with the first day of trading on Nasdaq First North Growth Market ("Nasdaq First North"), which is scheduled for June 14, 2023. The Document supplements, in accordance with Nasdaq First North’s rulebook, the prospectus published by Cereno Scientific on May 5, 2023 (the “Prospectus”).

The Document is to be read as a supplement to the Prospectus that the Company disclosed in connection with the recently completed rights issue which ended on May 24, 2023. The Document does not constitute a prospectus, has not been reviewed or approved by any regulatory authority and does not contain any offer of shares or other financial instruments. The Document and the Prospectus can be found on Cereno Scientific's website, www.cerenoscientific.com.

Cereno Scientific has received a conditional approval for the admission of the Company's shares of series B to trading on Nasdaq First North, which the Company announced on May 30, 2023. The first day of trading in the Company's shares of series B on Nasdaq First North is scheduled for June 14, 2023.

Advisors

Mangold Fondkommission AB is the Company's advisor in connection with the listing on Nasdaq First North and has been appointed as the Company's Certified Adviser. MAQS Advokatbyrå AB acts as legal advisor in connection with the listing on Nasdaq First North.

For further information, please contact:

Jonas Fogelberg, Interim CFO

Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno Scientific to use their cutting-edge technology CardioMEMS HF System in the study. Cereno Scientific also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno Scientific is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.